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Abstract
Background: Methamphetamine is one of the most toxic of the drugs of abuse, which may reflect its distribution and
accumulation in the body. However no studies have measured methamphetamine’s organ distribution in the human body.
Methods: Positron Emission Tomography (PET) was used in conjunction with [
11C]d-methamphetamine to measure its
whole-body distribution and bioavailability as assessed by peak uptake (% Dose/cc), rate of clearance (time to reach 50%
peak-clearance) and accumulation (area under the curve) in healthy participants (9 Caucasians and 10 African Americans).
Results: Methamphetamine distributed through most organs. Highest uptake (whole organ) occurred in lungs (22% Dose;
weight ,1246 g), liver (23%; weight ,1677 g) and intermediate in brain (10%; weight ,1600 g). Kidneys also showed high
uptake (per/cc basis) (7%; weight 305 g). Methamphetamine’s clearance was fastest in heart and lungs (7–16 minutes),
slowest in brain, liver and stomach (.75 minutes), and intermediate in kidneys, spleen and pancreas (22–50 minutes). Lung
accumulation of [
11C]d-methamphetamine was 30% higher for African Americans than Caucasians (p,0.05) but did not
differ in other organs.
Conclusions: The high accumulation of methamphetamine, a potent stimulant drug, in most body organs is likely to
contribute to the medical complications associated with methamphetamine abuse. In particular, we speculate that
methamphetamine’s high pulmonary uptake could render this organ vulnerable to infections (tuberculosis) and pathology
(pulmonary hypertension). Our preliminary findings of a higher lung accumulation of methamphetamine in African
Americans than Caucasians merits further investigation and questions whether it could contribute to the infrequent use of
methamphetamine among African Americans.
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Introduction
Methamphetamine is a highly addictive and toxic drug of abuse.
The high addictive potential of methamphetamine is believed to
reflect it potency in increasing dopamine in the nucleus
accumbens (pharmacological effect associated with drug reinforce-
ment) [1]. Methamphetamine also has potent central and
peripheral sympathomimetic effects, which are believed to
contribute to its toxic effects [2]. Methamphetamine is relatively
easy to manufacture, which has facilitated its availability
worldwide and contributed to increases in its abuse. This coupled
to its toxicity has resulted in an increase the number of medical
complications and fatalities associated with the abuse metham-
phetamine [3,4].
Methamphetamine’s medical complications affect multiple
organs [5]. In brain these include cerebral stroke, hemorrhage,
psychoses, seizures; in heart these include myocardial infarction,
arrhythmias, cardiomyopathy and ventricular hypertrophy; in lung
these include pulmonary edema and hypertension; and in kidneys it
includes acute renal failure [6]. Postmortem studies also report
pathological findings in the livers of methamphetamine absuers [7];
though this could reflect the high prevalence of hepatitis C infection
in this population rather than direct effects of the drug in tissue.
Nonetheless the widespread organ toxicity reported in metham-
phetamine abusers suggests that methamphetamine distributes and
is taken up by most organs of the human body as we recently
showed to be the case for non-human primates [8].
Here we evaluate the pharmacokinetics and distribution of
methamphetamine in the various organs of the human body. Since
the abuse of methamphetamine is very low among African
Americans (AA) when compared to Caucasians (C) [9,10] we also
compared the distribution of methamphetamine in the body
between AA and Caucasians C. For this purpose we used PET and
[
11C]d-methamphetamine to measure the whole body distribution
and pharmacokinetics of methamphetamine in vital organs of the
human body in healthy non drug abusing males (10 AA and 9 C).
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[
11C]d-Methamphetamine concentration in arterial blood
peaked at 50 seconds (0.00560.004 %Dose/cc) and half peak
clearance occurred at 90 seconds (Figure 1, Table 1). Percent
excretion of radiotracer in urine was 6.562.4 at 8764 min post
[
11C]d-methamphetamine injection and did not differ between AA
(6.962.7%) and C (5.962.2%).
[
11C]d-Methamphetamine distributed throughout the whole
body (Figure 1). The highest peak concentration (% Dose/cc)
occurred in kidneys and lungs followed by stomach, pancreas,
spleen, liver and lower values in heart and brain (Table 1). The
pharmacokinetics of [
11C]d-methamphetamine also differed
between organs; uptake was fastest in lung and heart (55–60
seconds), followed by spleen, kidneys and pancreas (3–5 minutes)
and brain (9 minutes) and was slowest in stomach and liver (30
minutes); clearance (half-peak clearance) was fastest for lungs (7
minutes), intermediate for heart (16 minutes), kidneys (22 minutes),
spleen (30 minutes) and pancreas (50 minutes) and slowest for
brain, stomach and liver (.75 min) (Table 2).
The comparisons between AA and C showed no differences in
plasma concentrationof radiotracer (Table 1),nor in the percentage
of unmetabolized radiotracer in plasma, which at 60 minutes
corresponded in AA to 72% and in C to 71%. Lung uptake of
[
11C]d-methamphetamine (expressed as % dose per cc/tissue) was
higher in AA (0.02560.005) than in C (0.01960.007) (p,0.05) but
did not differ in other organs (Figure 2, Table 1). The lung
accumulation of [
11C]d-methamphetamine (AUC) was 33% higher
in AA than C (p,0.5) but did not differ in other organs (Table 2).
Discussion
Here we show that [
11C]d-methamphetamine is widely
distributed in the human body and higher for some organs than
for brain (per/cc tissue). The widespread distribution of metham-
phetamine in the various organs of the body is consistent with our
prior findings in non human primates and rats in whom we
showed a similar organ distribution of [
11C]d-methamphetamine
[8,11] and with immunocytochemistry studies in mice [12]. In
humans we show that the uptake of [
11C]d-methamphetamine was
highest (per/cc tissue) in kidneys and lungs, intermediate in
stomach, pancreas, liver, spleen and lower in brain and heart
(Figure 1). This distribution differs markedly from that of cocaine
for which we showed that the highest uptake occurred in brain and
the lowest in lungs [13].
The lung, along with the kidneys, had the highest [
11C]d-
methamphetamine uptake and at peak approximately 24–31% of
the injected dose was in the lung (assuming a weight of 1246
grams). The uptake of [
11C]d-methamphetamine in lung was very
fast (peak 55 seconds) and is unlikely to just reflect its vascular
perfusion since the peak concentration in lung was much higher
than in arterial plasma and its clearance much slower (7 minutes vs
1.5 minutes). Lung accumulation could reflect uptake by
monoamine transporters since [
11C]d-methamphetamine is a
substrate for the dopamine, serotonin and norepinephrine
transporters [14] and/or non-specific binding. Of particular
clinical relevance would be its uptake by the serotonin transporter
since it is the one implicated in the higher risk for pulmonary
hypertension seen in methamphetamine abusers [15]. However, to
our knowledge there is currently no data showing that the
serotonin transporter is responsible for the uptake of metham-
phetamine in lungs.
A recent report revealed a greater risk of tuberculosis (TB)
infection among methamphetamine users than non-users [16].
Similarly a study of HIV-infected patients in Thailand reported
that 40% of those also infected with TB had a history of
methamphetamine use [17]. Though this probably reflects
Figure 1. Averaged time-activity curves of [
11C]d-metamphetamine in the various organs of the body. Note that the values correspond
to the average for all subjects (AA and C) whereas Table 2 reports separate values for AA and C, which is why they don’t exactly match.
doi:10.1371/journal.pone.0015269.g001
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methamphetamine abusers, we speculate that the high accumu-
lation of methamphetamine in the lungs may also contribute by
rendering pulmonary tissue more vulnerable to infections (or other
insults). Studies to evaluate the association between methamphet-
amine abuse and TB merit more careful evaluation.
The high accumulation of methamphetamine in kidneys (at
peak 7% of the injected dose was in the kidneys, assuming 305
grams for both kidneys) could reflect its high urine excretion,
which is likely to reflect both its active secretion by renal tubule
cells as well as its partition into an acidic urine (methamphetamine
is a weak base) [18,19]. It is estimated that 37–45% of an
intravenous or smoked dose of methamphetamine is excreted in
the urine as the parent drug and 6–7% as amphetamine within
72 hours of dosing (most of the excretion occurring within the first
20 hours) [18]. This is consistent with our urine measurements
which showed 10% of the injected dose was present in urine 90
minutes after injection of [
11C]d-methamphetamine.
In the pancreas (tail) the high uptake (per/cc tissue) of
methamphetamine could reflect uptake by dopamine transporters
and vesicular monoamine transporters, which are targets of
methamphetamine and are highly expressed in pancreatic tissue
[20] and may mediate the rapid increases in insulin that follow
acute methamphetamine administration [21]. Though to our
knowledge there are no published studies of methamphetamine
abuse and diabetes, a preliminary report of abnormal glucose
tolerance tests and aberrant insulin values in methamphetamine
abusers supports this possibility [22].
Methamphetamine’s accumulation in spleen was consistent with
similar findings in rats and in non-human primates [8,11]. In
rodents methamphetamine impairs splenic lymphocyte function
Table 1. Uptake and pharmacokinetics of [
11C]methamphetamine in the various organs.
Organ Peak time Half-peak clearance
Peak
% Dose/cc
Organ weight
% Dose organ AUC
Plasma
a
AA
C
50 sec 1.5 min
0.01460.002
0.01460.003
4500 grams
a
63%
63%
0.02960.004
0.03060.003
Lung
AA
C
55 sec 7 min
0.02560.005*
0.01960.007
1246 grams
b
31.2%
23.7%
0.39360.069*
0.29460.082
Heart
AA
C
1 min 16 min
0.00760.003
0.00760.001
365 grams
2.55%
2.55%
0.25960.072
0.20560.087
Kidneys
AA
C
3 min 22 mi
0.02260.004
0.02260.005
305 grams
b
6.7%
6.7%
0.73260.125
0.72060.167
Pancreas (tail)
AA
C
5 min 50 min
0.01360.002
0.01560.002
144 grams
1.9%
2.2%
0.51860.225
0.65560.239
Spleen
AA
C
3.5 min 30 min
0.01460.002
0.01360.002
156 grams
2.2%
2.0%
0.51360.101
0.50360.064
Liver
AA
C
30 min .75 min
0.01460.003
0.01360.002
1677 grams
23.5%
21.8%
0.87160.215
0.77860.138
Stomach
AA
C
30 min .75 min
0.01460.007
0.01760.005
330 grams
4.6%
5.6%
0.85560.215
0.96760.457
Brain
AA
C
9m i n .75 min
0.00660.001
0.00660.001
1600 grams
9.6%
9.6%
0.37160.043
0.38060.041
Measures correspond to: time to peak concentration (Peak time), time to half-peak clearance averaged across both groups and peak concentration (expressed as %
dose per cc) and AUC for the time activity curves for the African Americans (AA) and for the Caucasians (C).
*Unpaired Student t test (two tail) p,0.05.
aThe plasma value was extrapolated to whole blood assuming a 55% plasma volume.
bReflects the total weight of both left and right organs. Note that the total percent of organ accumulation is greater than 100%; this is because the times at which the
peak uptake and the clearance occurs differs among the organs. The weight of the organs corresponds to the average weights recorded from male autopsies [37];
except in brain, which corresponds to weights obtained with MRI
38.
doi:10.1371/journal.pone.0015269.t001
Table 2. Number of subjects in whom [
11C]d-
methamphetamine measures were obtained for the various
organs.
Organ African Americans (n=10) Caucasians (n=9)
Heart 8 7
Lungs 8 7
Kidneys 9 6
Stomach 9 7
Liver 10 7
Spleen 10 7
Pancreas 8 5
Brain 10 9
doi:10.1371/journal.pone.0015269.t002
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to the higher rate of infections in methamphetamine abusers (i.e.,
TB, HIV). However, this interpretation requires demonstration of
a causal relationship between local concentrations of metham-
phetamine and immunosuppression, which to our knowledge is
currently not available.
The heart had lower methamphetamine uptake than other
organs (2.6% injected dose at one min after injection) and its
retention in heart was very short lasting. This was unexpected
since cardiovascular events are among the most frequent medical
complications reported in methamphetamine abusers (review [6]).
Thus our findings are consistent with the belief that methamphet-
amine’s central and peripheral sympathomimetic effects rather
than direct effects to myocytes, are responsible for its cardiotoxic
effects (review [25]). Nonetheless, the good temporal correspon-
dence between methamphetamine’s fast accumulation in heart
(peaks 60 seconds) and the fast increases in blood pressure induced
by this drug (peaks at 60 seconds after iv administration), [26]
suggests that methamphetamine may also directly affect cardiac
tissue.
Brain uptake of methamphetamine was lower than in many of
the organs (per cc of tissue), which could contribute to its clinical
toxicity since significant organ accumulation will occur when the
drug is used for recreational purposes. This is distinct from cocaine
for which the brain uptake is higher than that observed in other
organs [13]. On the other hand methamphetamine’s clearance
from brain was very slow, which is likely to result in long lasting
exposure of the brain to the sympathomimetic effects of this drug
and contribute to its neurotoxicity. The neurotoxic effects of
methamphetamine have been extensively documented and are
believed to reflect both its vasoactive effects, which can result in
ischemia and necrosis as well as its cathecholaminergic effects,
which can result in damage to dopamine neurons, psychosis and
seizures [27,28].
The pharmacokinetics of [
11C]d-methamphetamine in the
stomach and liver were similar and were the slowest from all the
organs. The hepatic accumulation of [
11C]d-methamphetamine
was very high (22–24% injected dose; weight 1677 grams) and
presumably represents methamphetamine and its metabolites.
Some of the liver accumulation could reflect its uptake and
excretion through the gallbladder [29]. The unexpected high
accumulation in stomach is likely to reflect the acid environment
that favors the uptake of a basic drug such as methamphetamine.
We note that the accumulation in stomach was quite variable
among subjects, which could reflect in part differences in stomach
acidification [30].
[
11C]d-Methamphetamine’s uptake and accumulation in lung
was higher in AA than C. This is noteworthy since the prevalence
rates of methamphetamine use in AA are much lower than in C
[9,10]. Cultural factors as well as market factors in drug access are
likely to contribute to these differences. However, differences could
also reflect genetic factors that make AA more vulnerable to the
Figure 2. Whole body images of [
11C]d-methamphetamine in an African American (AA) and in a Caucasian (C) who received 7.18
and 6.99 mCi respectively and location of areas where ROI were obtained. Imaging was started 4 min post injection moving from head to
pelvis in 12 minute segments. The images have been decay corrected. Note the higher accumulation of [
11C]d-methamphetamine in the lung of the
AA than of the C. The hot spot on the abdominal cavity of the Caucasian corresponds to the stomach where [
11C]d-methamphetamine accumulation
was high but quite variable across subjects (may reflect its acidic environment that favors trapping of methamphetamine, which is a weak base).
doi:10.1371/journal.pone.0015269.g002
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and robust findings in the genetics of drug abuse are that of
‘‘protective’’ genes that confer an enhanced sensitivity to the
untoward effects of the drug (i.e., ALDH gene that leads to
impaired metabolism of alcohol and protection against alcoholism)
[31]. Similarly in rats an enhanced sensitivity to the aversive effects
of methamphetamine was associated with lower rates of drug self-
administration. Interestingly, the serotonin transporter gene was
implicated in this association [32].
The following are study limitations. First, PET measures the
concentration of carbon-11 and cannot ascertain if the measures
correspond to the drug or labeled metabolites. However, analysis
of the plasma revealed that 70–72% of the parent compound
remained at 60 minutes after injection indicating that the bulk of
carbon-11 in most organs corresponded to the parent compound.
Second, these studies were done at tracer doses of [
11C]d-
methamphetamine, which raises the question of whether the
pharmacokinetics of a tracer dose reflects that of a pharmacolog-
ically active dose (i.e., 0.5 mg/kg). However, the fact that the
pharmacokinetics of d-methamphetamine in the baboon brain
were not altered at behaviorally active doses [8] suggests that
tracer doses reflect those of pharmacological doses. Third, from
these studies we cannot determine whether methamphetamine’s
uptake (methamphetamine is a substrate for monoamine trans-
porters) is by specific reuptake sites or non-specific accumulation.
Fourth, methamphetamine is a mixture of levorotatory and
dextrorotatory isomers and here we report only on d-metham-
phetamine. Though this is the predominant form of methamphet-
amine sold in the streets some forms contain l-methamphetamine
and thus one could question whether this could result in a different
organ distribution from that of d-methamphetamine. This is
unlikely since we had previously shown no differences in the
uptake and distribution of carbon-11 labeled l- methamphetamine
and d- methamphetamine in non-human primates [33]. Finally,
the sample size was small and thus we are treating the differences
in pulmonary accumulation of [
11C]d-methamphetamine between
AA and C as preliminary and in need of replication.
In summary this study reports widespread distribution of
methamphetamine throughout most body organs, which is likely
to contribute to the serious medical conditions that affect
methamphetamine users. It also identifies differences in pulmo-
nary uptake of methamphetamine between AA and C that merits
further investigation.
Materials and Methods
Studies in Humans
Subjects. Ninteen healthy male controls (9 C and 10 AA),
matched for age (C 3967; AA 3665) were recruited by word of
mouth and newspaper advertisements. A complete physical and
neuropsychiatric examination was done to exclude physical
illnesses or neuropsychiatric disorders including substance use
disorders (illicit drugs, alcohol or nicotine). Care was taken to
ensure that subjects were not smokers, to avoid potential
confounds secondary to radiotracer retention in lungs [34].
Subjects were also excluded if they were currently (past 2 weeks)
on prescription or over the counter medications. A qualitative
immunoassay in urine was done prior to each PET scan to ensure
that no psychoactive drugs had been used. This study was carried
out at Brookhaven National Laboratory and approved by the local
Institutional Review Board (IRB of record: Committee on
Research Involving Human Subjects (CORIHS); Study #:
IRBnet #91581; CORIHS ID #2007-4835; BNL IRB #373)
and written informed consent was obtained from all participants.
Seventeen of the subjects underwent a torso dynamic scan and
for twelve of them, we were able to visualize both heart and
kidneys, but for five subjects we had to perform a second dynamic
torso scan to image thoracic and abdominal organs. We could not
visualize all of the organs on all of the subjects. Table 2 provides
the sample size for each organ for each of the races. Three of the
subjects underwent a segmented whole body scan. The subjects
also had two brain PET scans (with [
11C]d-methamphetamine and
with [
11C]cocaine, which were reported previously in a study that
compared the brain uptake of [
11C]d-methamphetamine and of
[
11C]cocaine [35]).
Radiotracer Synthesis. [
11C]d-Methamphetamine was
prepared from d-amphetamine and [
11C]methyl iodide as
described previously [8].
PET scanning. Dynamic PET imaging was carried out on a
Siemen’s HR+, whole body PET scanner (4.564.564.8 mm
FWHM at center of field of view) in 3D acquisition mode, 63
planes. For all scans, a transmission scan was obtained with a
68Ge/
68Ga rotating rod source before the emission scan to correct
for attenuation before each radiotracer injection. The specific
activity of [
11C]d-methamphetamine was 0.1860.09 Ci/
micromol at time of injection and the dose injected averaged
6.860.77 mCi. The radiochemical purity was .98% and the cold
compound injected averaged 9.666.9 micrograms. For the torso
dynamic scans scanning was carried out for 75 minutes with the
following time frames (1610 sec; 1265 sec; 1620 sec; 1630 sec;
8660 sec; 46300 sec; 66450 sec); for the abdomen and the brain
dynamic scanning was carried out for 90 minutes. For consistency
purposes we only report the data collected up to 70 minutes post
injection. For the segmented whole body scans, scanning from
brain to pelvis was begun 4 min post [
11C]d-methamphetamine
injection for a total of 7 segments (12 min/segments with 8
minutes emission and 4 minutes transmission). Thus the segment
of the image covering the brain is done at an earlier time (5–18
minutes after radiotracer injection) than the segment covering the
pelvis (72–80 min after radiotracer injection) so this must be taken
into account when viewing the whole body scan. Note that all of
the radioactivity measures are decay corrected.
In order to obtain time activity curves in all organs (located in
brain, thorax and abdomen) in a given subject we had to do at
least two separate studies with [
11C]d-methamphetamine (one to
cover the head and another to cover thorax/abdomen) and some
cases required a third study in order to get data in all of the organs.
Typically brain scans and torso scans were performed on the same
day with a two hour interval between them. When a third scan was
necessary to cover all of the peripheral organs, it was performed on
a separate day. Arterial blood was sampled automatically (Ole-
Dich, Denmark) and assayed for the concentration of parent
radiotracer in the arterial plasma [8]. The results for the
distribution of [
11C]d-methamphetamine in brain have been
published [35] and here we will only report on these to serve as
comparison with other organs.
In ten subjects (6 AA and 4 C) we collected urines at the end of
the study (8764 min post [
11C]d-methamphetamine injection) to
measure the percent of radiotracer excreted in urine.
Image Analysis
Time frames were added over the experimental period (75–
90 min), the planes of the summed images were summed in groups
of two for the purpose of region of interest (ROI) placement. In the
heart, elliptical ROI were placed directly across the wall of the left
ventricle and/or the interventricular septum for three consecutive
slices. Circular ROI were placed on each of 3 planes of the left
lung, liver, stomach and spleen using the Herbener Atlas as
Methamphetamine in Human Body
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tail of the pancreas (tail was selected to standardized the location of
ROI placement) and on 2–5 planes in left and right kidneys. For
the brain we averaged the activity in ROI located in cortical,
subcortical and cerebellar regions as described previously [35].
Carbon-11 concentration in each ROI was divided by the injected
dose and corrected by the subject’s weight to obtain the
concentrations of C-11 vs. time. We also measured the arterial
concentration of the radiotracer and the percentage of non-
metabolized radiotracer at different times during the scan. The
time activity curves (expressed as % injected dose/cc vs time) for
the various organs was obtained and used to measure the time to
reach peak concentration, the time to reach half-peak from
clearance and the area under the curve (AUC). Differences in
these measures between C and AA were tested using unpaired
student t tests (two-tail).
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